The Zika virus currently on a rampage in the Americas could easily spread to Asia where other mosquito-borne diseases like dengue fever and malaria are already endemic and drugmakers in the region, and elsewhere, are racing to come up with a vaccine.
Japan's ban on the combination vaccine for mumps, measles and rubella in routine immunizations, a cumbersome bureaucracy, and a lack of vaccine coverage in the country's healthcare program are putting the nation at risk, various officials and researchers claim.
Global health and trade organizations have been pushing for increased access to veterinary drugs, with groups such as HealthforAnimals and the World Organization for Animal Health laying out potential solutions. But vaccines could have the greatest impact on animal health, with experts in a new report calling vaccination the "biggest breakthrough" in the field in the past 100 years.
Prominent U.K. investor Neil Woodford has been calling for a four-way breakup of GlaxoSmithKline, a company he says is too "complicated" for its own good. But take it from GSK vaccines chief Moncef Slaoui--splitting apart is a bad idea, at least on the vaccines front.
SAN FRANCISCO-- Look out, Merck & Co.: GlaxoSmithKline expects its shingles candidate, Shingrix, to be a "major market disrupter" when it wins approval.
Geneva-based Gavi, the global vaccine alliance funded by the Bill and Melinda Gates Foundation and other donors, has pledged $500 million over the next 5 years to support India's country-wide immunization program.
For more than 40 years, a longtime Japanese drugmaker apparently carried out an elaborate subterfuge worthy of a grand conspiracy theory. Chemo-Sero-Therapeutic Research Institute, known as Kaketsuken, acknowledged violations and a massive cover-up lasting for decades.
GlaxoSmithKline is making a move to beef up its vaccine business in India and has started the ball rolling with a price cut on its pneumonia vaccine Synflorix and set the stage for two product launches in 2016, according to a report by the Business Standard.
Products that prevent diseases in animals are in hot demand these days--a trend that Zoetis demonstrated earlier this month, when it shelled out $765 million to buy Pharmaq, one of the world's leaders in vaccines for farmed fish. But Zoetis is also working hard to expand its presence in preventive health through its own internal research efforts, and that work seems to have paid off with two new product approvals.
After struggling out of the gate with Novartis' vaccines in hand, GlaxoSmithKline's vaccines unit turned its fortune in the third quarter and was able to deliver considerable increases in sales and profits.